AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
As of today, AstraZeneca(AZN) shares are valued at $154.73. The company's market cap stands at 242.69B, with a P/E ratio of 25.18 and a dividend yield of 1.85%.
On 2026-08-03, AstraZeneca(AZN) stock moved within a range of $153.41 to $162.75. With shares now at $154.73, the stock is trading +0.9% above its intraday low and -4.9% below the session's peak.
Trading activity shows a volume of 7.01M, compared to an average daily volume of 2.54M.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
AZN News
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...
The potential combination could create a pharmaceutical giant valued at nearly $400 billion. AstraZeneca holds an estimated market capitalization of $263 billio...
Wall Street Skepticism Meets Pharma Mega-Merger Rumors Reacting to reports of the massive transaction, Cramer asked in a post on X if the ongoing talks were an...
Analyst ratings
77%
of 31 ratingsMore AZN News
AstraZeneca (AZN) tops pharmaceutical growth rankings while Bristol Myers Squibb (BMY) trails, as the two drugmakers reportedly explore a potential merger that...
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Monday. AstraZeneca is reportedly in discussions with Bristol My...
AstraZeneca, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Citi maintained a Buy rating on the stock an...
Citi analyst Graham Parry is surprised by the Financial Times report of a potential merger between AstraZeneca (AZN) and Bristol Myers (BMY). The firm believes...
Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....
...
↗️↘️AstraZeneca (AZN, UK:AZN), Bristol Myers Squibb (BMY): The drug companies are in talks to combine in a deal that would value the joint company at roughly $4...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.